Alzheimers

Cognition Therapeutics Inc (NASDAQ:CGTX) rose 12.10% to $0.45 during after hours on Thursday, following a surge of 20.82% gain during regular hours.  What Happened: The hike in Cognition Therapeutics’ stock price is attributed to the promising results from its Alzheimer’s drug,...

Bank of America Securities has downgraded Alector, Inc. (NASDAQ:ALEC), citing the failure of its AL002 program. Alector recently released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s...

In a massive stride towards Alzheimer’s treatment, IGC Pharma (NYSE:IGC) recently revealed promising interim results for their pioneering drug, IGC-AD1, aimed at mitigating agitation in Alzheimer’s patients. This breakthrough is a beacon of hope for millions affected by this...

Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news.  The Analysts Raymond James' Laura Chico maintained a Market...

Shares of Biogen Inc (NASDAQ: BIIB) soared higher by more than 13 percent early Friday morning in reaction to the results of an Alzheimer's disease study.  What Happened Biogen and its Japanese partner Eisai Co released a final analysis of 856 patients in a Phase 2 clinical study in...

Pain Therapeutics, Inc. (NASDAQ: PTIE) shares took center stage Monday, offering pleasure rather than pain to those investing in the company. The shares of the clinical-stage biopharma company gap-opened up at $4.20, adding over 12 percent from the previous session's close of $3.74....

Analysts at Morgan Stanley turned bullish on Biogen Inc (NASDAQ: BIIB) as the company's phase 3 Alzheimer's catalyst could "make all its potential issues disappear." The firm's Matthew Harrison upgraded Biogen's stock rating from Equal-Weight to Overweight with a price target boosted from $311 to $...

Axovant Sciences Ltd (NASDAQ: AXON) suffered a setback in its phase 3 trial called MINDSET in which its exploratory drug called intepirdine failed to improve the quality of life in people suffering from Alzheimer's. The drug isn't intended to be a cure for the disease but the company expected the...

Axovant Sciences Ltd (NYSE: AXON) reported its fiscal fourth-quarter results on Tuesday, which helped push shares higher by more than 3.5 percent on Wednesday. Investors could potentially be rewarded with another upcoming catalyst in September with topline Phase 3 MINDSET results, analysts at HC...

Shares of Neurotrope Inc (NASDAQ: NTRP), a biopharmaceutical company focused on developing a therapy called bryostatin-1 for the treatment of Alzheimer's disease, lost more than half of its value on Monday after a planned release of clinical data failed to impress investors. Investors On A...

Shares of Neurotrope Inc (NASDAQ: NTRP), a clinical-stage biopharmaceutical company that develops therapies for the treatment of Alzheimer's and neurodegenerative diseases, shot higher by more than 15 percent early Friday morning. Neurotrope announced it will be releasing Monday top-line data...

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) gained more than 15 percent early Tuesday morning after the company announced positive top-line results from a Phase II study (-019 Study) of its therapy to treat Alzheimer's Disease called pimavanserin. Acadia's therapy has a different...

Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) surged more than 20 percent in Tuesday’s pre-market after it announced positive data from its Phase 2a study in mild-to-moderate Alzheimer’s patients. “At 41 weeks, Alzheimer’s patients taking a daily oral dose of ANAVEX 2-...

Biogen Inc (NASDAQ: BIIB) shares are being killed today after the company reported earnings that missed expectations and lowered guidance. Shares are trading down by more than 18 percent on Friday to below $315 at last. Michael Yee at RBC Capital Markets said that the stock may "take a bit of time...